Last reviewed · How we verify

Ibuprofen, Hydrocortisone — Competitive Intelligence Brief

Ibuprofen, Hydrocortisone (Ibuprofen, Hydrocortisone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + corticosteroid combination. Area: Inflammation, Pain Management.

marketed NSAID + corticosteroid combination COX-1, COX-2, glucocorticoid receptor Inflammation, Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ibuprofen, Hydrocortisone (Ibuprofen, Hydrocortisone) — X-pert Med GmbH. Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, while hydrocortisone suppresses immune and inflammatory responses through glucocorticoid receptor activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ibuprofen, Hydrocortisone TARGET Ibuprofen, Hydrocortisone X-pert Med GmbH marketed NSAID + corticosteroid combination COX-1, COX-2, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + corticosteroid combination class)

  1. X-pert Med GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibuprofen, Hydrocortisone — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-hydrocortisone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing